Key result
Cholesterol reduction cuts CHD death and non-fatal MI without increasing cancer or trauma deaths.
Why the study?
Randomised trials have shown cholesterol reduction decreases coronary heart disease incidence, but effects on trauma death, cancer death, and total mortality remain unclear.
Does cholesterol reduction therapy reduce coronary heart disease events and total mortality without increasing cancer or trauma deaths?
Meta-Analysis (n=50,000)
Does cholesterol reduction therapy reduce coronary heart disease events and total mortality without increasing cancer or trauma deaths?
Cholesterol reduction significantly reduces coronary heart disease events without a statistically significant increase in cancer or trauma deaths, supporting its overall safety and efficacy.
Cholesterol lowering cuts CHD events within years; leaves open the full mortality benefit and optimal populations for 10% reductions.
Randomised trials of cholesterol reduction (26 trials, 50,000 patients, net cholesterol reduction approximately 10%) have demonstrated a clear reduction in the incidence of coronary heart disease (CHD) after just a few years of treatment. Overall, the reduction in CHD death was only half as large as the reduction in non-fatal myocardial infarction (MI), although both were statistically significant (2P < 0.005). In these trials, 60% of all deaths were from CHD, and since treatment reduced these by about 10%, the expected reduction in total deaths was about 6%. This expected reduction falls within the 95% confidence interval of the observed effect of cholesterol reduction on total mortality in these trials. There were small excesses of deaths from cancer and deaths from trauma among patients allocated active treatment. However, in no single trial, nor in the trials collectively, were these increases statistically significant. Furthermore, the increases did not appear to be specific to any one agent nor were the increases consistent between trials of the same agent. These observations are consistent with the hypothesis that the small excesses of cancer and trauma deaths observed in the cholesterol reduction trials occurred by chance.
No takes yet. Share an insight, caveat, or question.
Stephen MacMahon (1992) conducted a meta-analysis in Coronary heart disease (n=50,000). Cholesterol reduction was evaluated on Coronary heart disease (CHD) death and non-fatal myocardial infarction (p=< 0.005). Cholesterol reduction significantly reduced CHD death and non-fatal myocardial infarction (2P < 0.005), with no statistically significant increase in cancer or trauma deaths.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: